Cristina Pernaut
Overview
Explore the profile of Cristina Pernaut including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Osorio L, Grazioso T, de Velasco G, Etxaniz O, Perez-Gracia J, Pinto A, et al.
Clin Transl Oncol
. 2024 Oct;
PMID: 39365364
Background And Purpose: Despite that incorporating antiangiogenic in combination with immune-checkpoint inhibitors as the standard first-line treatment for advanced clear cell renal cell cancer (ccRCC) yields promising outcomes, these regimens...
2.
Garcia-Donas J, de Velasco G, Madurga R, Chamorro J, Rosero D, Etxaniz O, et al.
Clin Transl Oncol
. 2023 Aug;
26(3):732-738.
PMID: 37556096
Background: Cancer is a risk factor for developing severe COVID19. Additionally, SARS-CoV2 has a special tropism for renal cells and complications like thrombosis or cytokine storm could be enhanced by...
3.
Carril-Ajuria L, Colomba E, Romero-Ferreiro C, Cerbone L, Ratta R, Barthelemy P, et al.
Eur J Cancer
. 2022 Dec;
180:21-29.
PMID: 36527973
Background: Immune checkpoint inhibitor-based combination therapy (ICI-based combination) is a new standard of care for metastatic clear cell renal cell carcinoma (mRCC) in the frontline setting. Patients with poor performance...
4.
Pernaut C, Lopez F, Ciruelos E
Breast Care (Basel)
. 2018 Oct;
13(4):244-249.
PMID: 30319326
Neoadjuvant treatment allows us to improve surgical results and test new drugs. In recent years, there have been significant advances in the field of neoadjuvant treatment, including hormonal neoadjuvant therapy...
5.
Cala M, Agullo-Ortuno M, Prieto-Garcia E, Gonzalez-Riano C, Parrilla-Rubio L, Barbas C, et al.
J Cachexia Sarcopenia Muscle
. 2018 Feb;
9(2):348-357.
PMID: 29464940
Background: Cachexia is a metabolic syndrome that affects up to 50-80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including...
6.
Pascual T, Apellaniz-Ruiz M, Pernaut C, Cueto-Felgueroso C, Villalba P, Alvarez C, et al.
PLoS One
. 2017 Jul;
12(7):e0180192.
PMID: 28727815
Purpose: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there...
7.
Rodriguez Garzotto A, Cortijo Casacajares S, Pernaut C, Ruiz Ares G, Otero Blas I, Heine O, et al.
J Blood Med
. 2014 May;
5:43-8.
PMID: 24855398
Background: The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis-stimulating agent (ESA; Binocrit(®)), and other available ESAs for the treatment of...